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Abstract: Classical approaches to African swine fever virus (ASFV) vaccine development have not
been successful; inactivated virus does not provide protection and use of live attenuated viruses
generated by passage in tissue culture had a poor safety profile. Current African swine fever (ASF)
vaccine research focuses on the development of modified live viruses by targeted gene deletion
or subunit vaccines. The latter approach would be differentiation of vaccinated from infected
animals (DIVA)-compliant, but information on which viral proteins to include in a subunit vaccine
is lacking. Our previous work used DNA-prime/vaccinia-virus boost to screen 40 ASFV genes
for immunogenicity, however this immunization regime did not protect animals after challenge.
Here we describe the induction of both antigen and ASFV-specific antibody and cellular immune
responses by different viral-vectored pools of antigens selected based on their immunogenicity in
pigs. Immunization with one of these pools, comprising eight viral-vectored ASFV genes, protected
100% of pigs from fatal disease after challenge with a normally lethal dose of virulent ASFV. This data
provide the basis for the further development of a subunit vaccine against this devastating disease.
Keywords: African swine fever virus; viral-vector; adenovirus; modified vaccinia Ankara (MVA);
vaccine; pathology
1. Introduction
African swine fever virus (ASFV) is the etiological agent of a disease of domestic pigs and wild boar
that is typically fatal and for which there is no vaccine or prophylactic. The disease was first reported in
the early 20th century and is considered endemic in sub-Saharan Africa. ASFV first appeared in Europe
in 1957 and again in 1960 in Portugal wherefrom the virus became established in the Iberian Peninsula
and from there caused outbreaks across Western Europe as well as in the Caribbean and Brazil. Early
experiments showed that passage of the virus through tissue culture led to its attenuation and that
pigs immunized with these attenuated viruses were protected from acute disease after challenge with
homologous strains. Such attenuated viruses were used in the Iberian Peninsula in the early 1960s,
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however their efficacy in the field was not satisfactory and induced a chronic form of the disease [1–3].
With the exception of the island of Sardinia, ASF was eradicated outside of Africa by the mid-1990s,
however it returned to Georgia in 2007 and has since spread throughout Eastern Europe and Eastern
Asia. Millions of animals have been killed by the virus or destroyed in attempts to control the disease.
Current approaches to ASF vaccine design concentrate on rational attenuation of virulent viruses
by targeted gene deletion [4–10] or development of subunit vaccines. The latter approach has been
limited by the choice of a delivery system and knowledge of protective antigens [11]. To date, protein,
DNA and viral vectored ASFV subunit vaccines have been tested in challenge studies. Recombinant
p30, p72, p54 and p22 (encoded by the CP204L, B646L, E183L and KP177R genes respectively) induced
neutralizing antibodies in pigs, but did not protect the animals from fatal disease [12]. However,
an E183L-CP204L fusion protein also induced neutralizing antibodies in pigs and did protect the animals
from severe disease after challenge [13]. Recombinant CD2v (EP402R) induced an antibody response
in pigs capable of inhibiting hemadsorption of red blood cells to ASFV-infected macrophages and
protected two out of three animals from fatal disease after challenge with virulent ASFV [14]. A DNA
vaccination approach using a fusion of the E183L, CP204L and the extracellular domain of EP402R did
not protect animals unless they were also fused to ubiquitin [15]. This approach has been extended to
immunization with a library of ASFV genomic DNA fragments, which protected 60% of pigs from
a fatal disease [16]. Interestingly a combinatorial approach of DNA-prime followed by protein-boost
that included EP402R, CP204L and E183L did not protect animals from fatal disease despite inducing
antigen-specific responses [17].
We and others have shown the utility of viral vectors as a route to express ASFV antigens in
pigs and induce antigen-specific antibody and cellular immune responses [18–23]. A pool comprised
of the ASFV genes A151R, B646L (p72), C129R, CP204L (p30), CP530R (pp62), E146L, I73R, I125L,
L8L, M448R, MGF110-4L and MGF110-5L vectored by replication-deficient human adenovirus 5 (rAd)
prime and modified vaccinia Ankara (MVA) boost led to reduced clinical signs and reduced levels
of viremia in a proportion of pigs after challenge with the virulent OUR T88/1 isolate [21]. B646L
(p72), CP204L (p30), CP530R (pp62), E183L (p54) in combination with the mature p37 product and two
sections of the mature p150 protein of the pp220 polyprotein (CP2475L gene) have been delivered to
pigs using an rAd homologous prime and boost strategy with two different adjuvants [18,22]. After
challenge with the Georgia 2007/1 isolate, 55% of the animals in one of the adjuvanted groups survived
to the end of the experiment, however, interpretation of this result is complicated by the observation
that the challenge model did not result in clinical signs typical of acute ASF in all of the controls [22].
One complicating factor in designing subunit vaccines to ASFV is that certain antigens, or combinations
of antigens, can induce enhanced disease in swine [15,21,22]. The mechanism(s) and the individual
antigens responsible for the vaccine-induced enhanced disease are unclear, but DNA vaccination
experiments showed a clear link between the induction of antibodies to the CP204L, E183L and EP402R
fusion protein and enhanced disease [15]. However, experiments with live attenuated viruses suggest
a role for both humoral [24,25] and cellular [26–28] responses in protection against virulent strains
of ASFV and therefore a subunit vaccine may need to induce both arms of the immune response for
effective protection.
Taken together, these results suggest that a viral-vectored vaccine against ASF is a feasible approach,
however, the choice of antigens is key to success. In a previous study, we immunized domestic pigs
with pools of ASF antigens using a DNA-prime/vaccinia virus-boost regime and identified antibody
responses by ELISA and cellular responses by ELIspot using recombinant protein as recall antigens.
The DNA-prime/vaccinia virus-boost approach identified a novel subset of immunogenic antigens, but
the immunization regime did not affect the clinical progression of disease after challenge, although
reduced viremia was seen three days post-infection and a reduced viral load in some tissues was
observed at termination [29]. We, therefore, decided to refine our approach, using rAd prime and
MVA boost as a delivery system with the antigens shown as immunogenic ex-ASFV. Here we show
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that a combination of eight different antigens can protect pigs from fatal disease after challenge with
a virulent genotype I strain of ASFV.
2. Materials and Methods
2.1. Antibodies
Monoclonal antibody C18 against CP204L (p30) has been described previously [30]. Rat anti-HA
monoclonal antibody 3F10 was purchased from Roche, mouse anti-V5 monoclonal antibody SV5-PK1
was from BioRad (CA, USA), and mouse anti-porcine IFNγ monoclonal antibodies P2F6 and P2C11
were from Thermo-Fisher Scientific.
2.2. Viruses and Cells
Tissue cultured adapted Ba71v and virulent OUR T88/1 ASFV strains have been described
previously [31,32]. OUR T88/1 was grown and titrated on bone marrow cells prepared from the femurs
of four to six-week-old Large White outbred pigs, Ba71v was grown on Vero cells. Bone marrow
cells were cultured for 3 days in EBSS (Sigma-Aldrich, Gillingham, UK) supplemented with 4 mM
HEPES, 10% heat-inactivated porcine serum (BioSera) and 100 IU/mL penicillin and 100 µg/mL
streptomycin (Sigma-Aldrich, Gillingham, UK) in plastic multi-well plates or culture flasks prior to
infection. Vero cells were maintained in DMEM-HEPES supplemented with 10% heat-inactivated foetal
calf serum and 100 IU/mL penicillin and 100 µg/mL streptomycin. A mock inoculum was prepared
from uninfected cell cultures. Infectious virus titres were determined by end-point dilution using
the Spearman–Karber method as the amount of virus causing hemadsorption in 50% of infected
cultures (HAD) or as the amount of virus causing 50% of cells staining positive for ASFV early protein
p30 by immunofluorescence (infectious units (IU). PBMC were cultured in RMPI GlutaMAX (Thermo
Fisher, Hemel Hempstead,UK), 25 mM HEPES supplemented with 10% fetal calf serum, 1 mM sodium
pyruvate, 50 µM 2-mercaptoethanol, 100 IU/mL penicillin and 100 µg/mL streptomycin (RPMI/10).
ASFV genomic DNA was detected using real-time quantitative polymerase chain reaction (qPCR)
as previously described [33]. Nucleic acid was extracted in duplicate using the MagMax Universal
Extraction kit (Thermo Fisher, Hemel Hempstead,UK), and each extraction subject to duplicate qPCR.
Data points represent the mean of these duplicate qPCR. For experiment 2, virus antigen was detected
in the bloodstream five days post-infection using ASFV-specific lateral flow devices (INgezim ASF
CROM Ag, Ingenasa, Madrid, Spain).
2.3. Recombinant Vectors
Vectors expressing influenza NP, B646L (p72) and CP204L (p30) have been described
previously [21,34]. ASFV open reading frames (ORFs) were codon-optimized for expression in
Sus scrofa, synthesized and cloned into pcDNA3.1zeo(+) (Thermo Fisher, Hemel Hempstead,UK).
Complete ORFs were synthesized with an HA tag at the 3′-end. Gene sequences were derived
from the genotype I OUR T88/3 isolate of ASFV with the exception of the EP153R and MGF360-11L
genes which were from the genotype I Benin 1997/1 isolate [35]. ASFV ORFs were then sub-cloned
into transfer plasmids for making recombinant replication-deficient human adenovirus 5 (rAd) and
recombinant modified vaccinia Ankara (MVA) using standard techniques. Purified viral vectors were
generated by the Jenner Institute Viral Vector Core Facility (Oxford, UK) [36,37]. The MVA transfer
plasmids, and hence the final viral vectors, also contained GFP under the control of a viral promoter to
enable rapid plaque purification of positive clones. All the vaccine vectors expressed protein products
of the expected sizes (Figures S1–S3) including proteins consistent with the glycosylated forms of
EP153R and I329L.
A plasmid containing the V5 epitope sequence was created by ligating overlapping oligonucleotides
into restriction endonuclease digested pcDNA3.1zeo (+). Codon-optimized ASFV genes E199L, EP153R,
EP364R, F317L, I329L, MGF360-11L, MGF505-4R and MGF505-5R were then amplified by PCR and
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sub-cloned in frame with the V5 epitope to create C-terminally tagged expression plasmids and
confirmed by sequencing.
2.4. Swine Leucocyte Antigen (SLA) Genotyping
Genotyping of three SLA class I (SLA-1, SLA-2, SLA-3) and three class II (DRB1, DQB1, DQA)
genes was performed using low-resolution PCR-based assays with sequence-specific typing primers
as previously described [38,39]. Modifications were made to the typing primer panels to broaden
the allele coverage with the increasing number of SLA alleles. SLA haplotypes were deduced based on
comparison with published haplotypes [38,40–42].
2.5. Animal Experiments and Ethics Statement
All of the animal experiments were carried out under the Home Office Animals (Scientific
Procedures) Act (1986) (ASPA) and were approved by the Animal Welfare and Ethical Review Board
(AWERB) of The Pirbright Institute and the AWERB of the Animal and Plant Health Agency (APHA),
Weybridge. Prime and boost with viral vectors were carried out at APHA. The animals were housed in
accordance with the Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for
Scientific Purposes, and bedding and species-specific enrichment were provided throughout the study
to ensure high standards of welfare. Through careful monitoring, pigs that reached the scientific or
humane endpoints of the studies were euthanized by an overdose of anesthetic (see Supplementary
data). All procedures were conducted by Personal License holders who were trained and competent
and under the auspices of Project License PPL70/8852.
Female Landrace × Large white pigs were obtained from a high health farm in the UK and
randomly assigned to each group prior to immunization. Scoring of clinical signs and macroscopic
lesions assessed at post-mortem were as described previously [27,43].
2.5.1. Experiment 1
Groups of six, eight-week-old, outbred pigs were inoculated intramuscularly in the neck with
rAd expressing the influenza nucleoprotein (PR8 strain) (Control, pigs 270 to 275), a pool of eight rAd
expressing ASFV ORFs (Antigen Pool A, pigs 264 to 269) or a pool of eight different rAd expressing
ASFV ORFs (Antigen Pool B, pigs 276 to 281) (Table 1). Each rAd expressing ASFV genes was
administered at a dose of 5 × 10 9 IU, and the controls were immunized with an equivalent total
dose of control rAd, therefore all animals were primed with a total of 4 × 1010 IU rAd per pig. Four
weeks later, the pigs were inoculated in the same site with MVAs expressing the same ORFs with
the exception of EP364R, I329L, MGF505-4R and MGF505-5R where rAd was used instead as MVAs
expressing these genes were not available. Each MVA expressing an ASFV gene was administered at
a dose of 7.5 × 107 pfu and each rAd at a dose of 5 × 109 IU. Animals in the control group were given
the equivalent of seven doses of MVA and two of rAd. Therefore, the Control group was boosted with
a total of 3.8 × 108 pfu MVA and 2 × 1010 IU rAd, Antigen Pool A with a total of 5.25 × 108 pfu MVA
and 5 × 109 IU rAd and animals given Antigen Pool B a total of 3 × 108 pfu of MVA and 2 × 1010 IU rAd
per pig. Four weeks later, the animals were challenged by the intramuscular route in the rump with
10,000 HAD OUR T88/1. Whole blood and heparinized blood was collected before each immunization
(Days 0 and 28) and two weeks after each immunization (Days 14 and 42). Blood was also collected
before (Day 59) and seven days after challenge (Day 66) with ASFV.
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Table 1. Composition of Antigen Pools. The individual HA-tagged ASFV genes in each pool and
the dose of each individual vector used in the prime and/or boost are indicated. Genes highlighted in
bold were administered by rAd prime and MVA boost whereas those shown in italics by rAd prime
and rAd boost.
Experiment 1 2
Antigen Pool A B A C
Genes
B602L B602L B602L B646L
B646L EP153R B646L CP204L
CP204L EP364R CP204L E199L
E183L F317L E183L F317L




rAd Dose (IU) 5 × 109 5 × 109 1.5 × 1010 1.5 × 1010
MVA Dose (pfu) 7.5 × 107 7.5 × 107 2 × 108 2 × 108
2.5.2. Experiment 2
Groups of six, eight-week-old, outbred pigs were inoculated intramuscularly in the neck with
rAd expressing the influenza nucleoprotein (PR8 strain) (Control, pigs 455 to 460), a pool of eight rAd
expressing ASFV ORF (Antigen Pool A, pigs 461 to 466) or a pool of five rAd expressing ASFV ORFs
(Antigen Pool C, pigs 449 to 454) (Table 1). Each rAd was administered at a dose of 1.5 × 1010 IU and
the controls were immunized with an equivalent total dose. Therefore, animals are given the control
antigen and Antigen Pool A were primed with a total of 1.2 × 1011 IU rAd per pig and those given
Antigen Pool C a total of 7.5 × 1010. Four weeks later, the pigs were inoculated in the same site with
MVAs expressing the same ORFs with the exception of MGF505-5R where rAd were used instead.
Each MVA expressing an ASFV gene was administered at a dose of 2 × 108 pfu and each rAd at
a dose of 1.5 × 1010 IU. Animals given NP Control were boosted with a total of 1.2 × 109 pfu MVA,
Antigen Pool A with a total of 1.4 × 109 pfu MVA and 1.5 × 1010 IU rAd and animals given Antigen
Pool C a total of 8 × 108 pfu of MVA and 1.5 × 1010 IU rAd per pig. Four weeks later the animals
were challenged by the intramuscular route in the rump with 10,000 HAD OUR T88/1. Whole blood
and heparinized blood was collected before each immunization (Days 0 and 28) and two weeks after
each immunization (Days 14 and 42). Blood was also collected before (Day 59) and seven days after
challenge (Day 66) with ASFV.
2.6. Interferon Gamma (IFNγ) ELISpot
Peripheral blood mononuclear cells (PBMC) were purified from heparinized blood using
histopaque (Sigma-Aldrich, Gillingham, UK) gradients and then washed extensively with PBS.
The response to ASFV was analyzed after in vitro stimulation of fresh cells, however, the response
to peptides was analyzed using cells that had been frozen, where viability was ≥90% after thawing.
Only samples from animals for which there was sufficient material to test antigen-specific responses
at all relevant time points were analyzed in this way. PVDF membrane multiwell plates (Millipore,
Abingdon, UK. MAIPS4510) were coated overnight at 4 ◦C with 4 µg/mL anti-porcine IFNγ (P2F6) in
0.5 M carbonate-bicarbonate coating buffer and then washed with PBS. Cells were plated in duplicate at
two different dilutions, typically 5 × 105 and 2.5 × 105 per well in RMPI/10. Cells were then incubated
overnight in a final volume of 200 µL with media alone, 0.5% DMSO, 105 HAD of OUR T88/1 or
an equivalent volume of mock inoculum, or 2.5 µg/mL PHA, or peptide pools. Twenty-mer peptides
overlapping by 10 amino acids were supplied at 1 to 3 mg scale (Mimotopes). The maximum amount of
peptides in any one pool was 24 and therefore there was at most 72 µg of peptides per well, with each
individual peptide being at a final concentration of 5 to 15 µg/mL. The molecular mass of the peptides
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varied between 1737.86 and 2758.11, therefore the final molarity of the peptides varied between 1.8 and
8.6 µM. Cells were lysed by incubating for 5 min in water and then washed with PBS. Biotinylated
anti-porcine IFNγ (P2C11), followed by streptavidin-conjugated to alkaline phosphatase, and then
AP Conjugate Substrate Kit (Bio Rad, Kidlington, UK) was used to visualize spots, which were then
counted using an ELIspot Reader System (Autoimmun Diagnostika, Strasberg, Germany). The number
of spots was converted into the number of spots per million cells and the mean of duplicate wells
plotted. In experiments where the number of IFNγ secreting cells was measured over time, the response
to the background (the highest of media/mock/DMSO) was subtracted from the response to whole
virus or peptide—this is indicated in the figure legends.
2.7. Fixed-Cell Assays
2.7.1. Immunoperoxidase Assay (IPA) against the Whole Virus
Anti-ASFV antibody titres were determined using an immunoperoxidase assay, by incubating
two-fold serial dilutions of sera on Ba71v-infected Vero cells fixed 16 h post-infection with 4%
paraformaldehyde [44]. Cells were permeabilized with 0.2% Triton X-100, blocked with 5% milk in
PBS-0.05% Tween 20 for one hour, then incubated with diluted sera for another hour and finally with
HRP-protein A conjugate (Thermo Fisher, Hemel Hempstead, UK). Cells were washed five times
with PBS 0.05% Tween20 between each step. Positive wells were identified by AEC staining (2 mM
3-amino-9-ethylcarbazole and 0.015% H2O2 (Sigma-Aldrich, Gillingham, UK) diluted in 50 mM sodium
acetate buffer). All pigs showed non-specific background staining of uninfected cells after incubating
with day 0 sera at dilutions varying from 1:16 to 1:128.
2.7.2. Immunofluorescence Assay (IFA) against Individual Proteins
The presence of antibodies to individual proteins was determined using indirect
immunofluorescence. Sera were used at a single dilution of 1:100 and incubated with Vero cells
transfected with each of the individual genes fused to a V5 tag. Pre-immunization and pre-challenge
sera were tested from pigs immunized with the pools of viral vectors expressing ASFV ORFs. Only
pre-challenge sera from pigs immunized with the control antigens were analyzed for antibodies to
ASFV proteins. Mouse anti-V5 tag (AbD Serotec, Oxford, UK. MCA1360) diluted 1:1000 was used as
a positive control for V5 fusion gene expression. In indirect immunofluorescence, the anti-V5 antibody
was incubated simultaneously with the animal sera on transfected cells. Secondary antibodies were
goat anti-mouse IgG (H+L)-AF594 (Thermo Fisher, Hemel Hempstead, UK) and goat anti-porcine
IgG (H+L)-AF488 (Southern Biotech, Birmingham, UK), all added at a dilution of 1:1000 to the cells.
The cells were then observed under the fluorescence microscope and screened for simultaneous green
and red fluorescence, resulting from recognition by specific antibodies in the pig serum of the expressed
viral protein and the presence of the V5 tag respectively.
2.8. Indirect ELISA
CP204L, B602L and B646L indirect ELISAs were carried out as previously described [45]. Maxisorp
ELISA plates (Nunc) were coated with ASFV recombinant proteins (50µL per well) diluted (1–10 µg/mL)
in coating buffer (50 mM sodium carbonate/bicarbonate buffer, pH 9.6) and incubated overnight at
4 ◦C. The wells were then washed three times with PBS plus 0.05% Tween 20 and blocked with PBS
plus 5% milk (200 µL per well) at 37 ◦C for 1 h. After blocking, plates were washed five times as
above and incubated for 1 h at 37 ◦C with pig sera diluted 1:100 in PBS plus 5% milk (50 µL per well).
The plates were again washed five times and incubated with protein A–horseradish peroxidase (Pierce)
diluted 1:5000 (100 µL per well) for 1 h at 37 ◦C. Finally, plates were washed again and developed with
3-dimethylaminobenzoic acid/3-methyl-2-benzothiazolinone hydrazine hydrochloride/H2O2 dissolved
in 0.1 M phosphate buffer. After stopping the reaction with 3 M H2SO4 (50 µL per well), the absorbance
at 620 nm was read on a Cytation3 microplate reader (Biotek, Swindon, UK).
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2.9. Statistical Analysis
Statistical analysis was performed with GraphPad Prism 8 (GraphPad Software, San Diego, CA,
USA). Unless stated otherwise two-way repeated measures ANOVA with the Geisser–Greenhouse
correction and Tukey’s multiple comparison test was used to compare data between and within groups
of animals. F ratios are reported in form F (dfn, dfd) = x, where dfn indicates the degrees of freedom
for the numerator and dfd the degrees of freedom of the denominator.
3. Results
3.1. Pools of Eight Viral Vectors Induce ASFV-Specific and Antigen-Specific Responses in Swine
In experiment 1 two groups of six outbred pigs were primed with two separate pools of eight
replication-deficient human adenovirus 5 (rAd) vectors expressing individual ASFV genes and another
group of six pigs was immunized with rAd expressing the influenza virus nucleoprotein as a control.
Antigen Pool A contained the ASFV genes B602L, B646L (p72), CP204L (p30), E183L (p54), E199L,
EP153R (C-type lectin), F317L and MGF505-5R, whereas Antigen Pool B contained the genes B602L,
EP153R, EP364R, F317L, I329L, MGF360-11L, MGF505-4R and MGF505-5R (Table 1). Following on from
our previous work, gene sequences were derived from the genotype I ASFV isolate OUR T88/3 as
immunization with this virus can protect pigs from OUR T88/1 and Benin 1997/1. Since EP153R and
MGF360-11L are either deleted or truncated in the OUR T88/3 genome sequences for these two genes
were derived from the closely related genotype I isolate Benin 97/1. Four weeks later, the animals
were boosted with the same pools of antigens vectored using rAd or modified vaccinia Ankara (MVA).
Approximately four weeks post-boost (59 days post-prime), the animals were challenged with the
virulent OUR T88/1 strain of ASFV. Immunization with both pools of ASFV antigens induced antibodies
that reacted with ASFV-infected cells (Figure 1A). Non-specific staining of Vero cells was detected in
pre-immune sera from all of the pigs but significant differences from the background were induced by
Antigen Pool A at all times points post-prime (p ≤ 0.0008, F(15, 60) = 4.302) and by Antigen Pool B after
boost (p ≤ 0.0273, F(15, 60) = 4.302). Antibody titers against infected cells were higher pre-challenge
than pre-boost in both groups of pigs (Pool A, p = 0.0047, Pool B; p = 0.0303; F (15, 60) = 4.302)
suggesting that the boost may have increased the level of ASFV-specific antibodies in circulation,
however, there was no difference in titers between the two groups of pigs. Indirect ELISAs were used
to detect antibodies against B602L, CP204L, E183L and IFA to detect antibodies against F317L, EP364R
and I329L in serum from different animals in the two groups (Figure 1B–F; Table 2), although antibodies
to EP364R were only found in one animal. No antibodies were detected to B646L by indirect ELISA or
to EP153R, MGF360-11L, MGF505-4R or MGF505-5R by IFA.
Table 2. Vero cells transfected with the individual antigens were stained with serum taken from
the individual pigs before immunization or before the challenge. Wells were incubated with serum
diluted 1:100 and anti-V5 antibody, then goat anti-pig and -mouse antibodies conjugated to Alexa Fluor
488 and 568 respectively. A pig was considered positive for a given antigen if the pre-immunization
sera were negative and the pre-challenge sera were positive. A dash indicates the sample was not
tested against this protein.
Protein
Antigen Pool A Antigen Pool B
264 265 266 267 268 269 276 277 278 279 280 281
E199L No No No No No No - - - - - -
EP153R No No No No No No No No No No No No
EP364R - - - - - - No No No No No Yes
F317L Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
I329L - - - - - - Yes Yes Yes No No Yes
MGF360-11L - - - - - - No No No No No No
MGF505-4R - - - - - - No No No No No No
MGF505-5R No No No No No No No No No No No No
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Figure 1. Antibody responses in pigs from experiment 1 primed with rAd encoding Antigen Pool A
(blue), Antigen Pool B (red) or influenza NP (green). Animals were boosted with rAd/MVA 28 days
after priming and challenged with ASFV 59 days after priming. (A) The titer of anti-ASFV antibodies
in the serum of the indicated animals was determined by immunoperoxidase assay. Antibodies to
ASFV proteins B646L (B), B602L (C, D), CP204L (E) and E183L (F) were detected in 1:100 dilutions of
serum collected from the indicated animals at the indicated times post-prime by ELISA, and expressed
as the absorbable at 620 nm. Timing of boost (Bo) and challenge (Ch) are indicated on panels B to F.
Differences between antibody titres were assessed by repeated-measures two-way ANOVA,* p ≤ 0.05,
** p ≤ 0.01.
Antigen Pool A induced ASFV-specific interferon gamma (IFNγ) secreting cells in the circulation,
with pigs 264 and 266 having consistently higher numbers during the course of the experiment
(Figure 2A). The levels of IFNγ secreting cells induced by Antigen Pool B were generally lower than
those seen in animals immunized with Pool A, although responses above background were seen in all
the animals except for 277. Consistent with our previous data, MVA boost did not significantly increase
the numbers of ASFV-specific IFNγ secreting cells [21]. Pools of overlapping peptides corresponding
to the individual proteins, or portions of the larger proteins, were used to identify antigen-specific
cellular responses over time in two animals from each of the groups that were immunized with Antigen
Pool A or Antigen Pool B (Figures 2 and 3). Specific cellular responses were observed in at least one
pig to all of the antigens in both Antigen Pool A and Antigen Pool B.
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Figure 2. Virus and antigen-specific IFNγ responses in animals from experiment 1 immunized
with Antigen Pool A (blue), Antigen Pool B (red) or Influenza NP (green). (A) The number of
ASFV-specific IFNγ producing peripheral blood mononuclear cells (PBMC) were enumerated by
ELIspot, on the indicated days post-prime, following in vitro stimulation with ASFV or peptides. Data
points indicate the number of spots per million cells induced by the whole virus after background
subtraction. (B–O). The number of IFNγ-producing PBMC stimulated by pools of peptides was
enumerated by ELIspot on the indicated days post-prime. N, mid and C indicate pools of peptides that
correspond to the N-terminus, mid-section or C-terminus of the proteins encoded by B602L, B646L,
F317L and MGF505-5R. Data points indicate the number of spots per million cells induced by the pool of
peptides after background subtraction, error bars indicate standard deviation from the mean. Note that
to aid clarity the scale for the virus-specific responses (A) have been set to half the range of the peptide
pools (B–O). Timing of boost (Bo) and challenge (Ch) are indicated on panels B to O.
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Figure 3. Antigen-specific IFNγ responses to Antigen Pool A (I, blue) or Antigen Pool B (A–I, red).
Numbers of IFNγ-producing PBMC stimulated by pools of peptides were enumerated by ELIspot
on the indicated days post-prime. N, mid and C indicate pools of peptides that correspond to
the N-terminus, mid-section or C-terminus of the proteins encoded by EP364R, I329L, MGF360-11L
and MGF505-4R. The response to MGF300-2L, an ASFV gene that was not part of either pool is also
shown. Data points indicate the number of spots per million cells induced by the pool of peptides after
background subtraction. Timing of boost (Bo) and challenge (Ch) are indicated.
3.2. Comparative Evaluation of Temperatures, Clinical Signs and Viremia Levels in Experiment 1
Beginning three days post-challenge with the virulent OUR T88/1 strain of ASFV, pigs immunized
with Antigen Pool A or influenza NP showed body temperatures above 40.5 ◦C (Figure 4D,G). Four
days post-challenge temperatures above 40.5 ◦C, and in many cases above 41 ◦C, were detected in
the rest of pigs belonging to the different experimental groups (Figure 4D,G,J). Increases in temperature
were accompanied by an increase in non-specific clinical signs (lethargy, reduced appetite) whose
severity increased as the disease progressed. With the exception of pigs 264 and 266 immunized
with Antigen Pool A, which showed a decrease in temperatures and clinical scores from six days
post-challenge (Figure 4G,H), temperatures and clinical scores remained high in the rest of pigs
belonging to the different experimental groups, so that animals were euthanized after reaching
the humane end-point between four and six days post-challenge. However, pigs 264 and 266
immunized with Antigen Pool A were maintained for twenty days after challenge and did not show
any clinical signs after they had recovered from fever during the first week.
Average temperatures (p = 0.0025; F = (7, 105) = 39.94) and clinical scores (p = 0.0085;
F (7, 105) = 90.05) in animals immunized with Antigen Pool B were lower than the controls three days
post-challenge, but not on the following day (Figure 4A,B). The clinical scores observed in the controls
were higher than those in animals immunized with Antigen Pool A (p = 0.0085; F (7, 105) = 90.05)
four days post-challenge. Three days post-challenge, viremia levels were approximately 10,000 or
1000 less than the controls in the groups of pigs immunized with Antigen Pool A and Antigen Pool B
respectively (one-way ANOVA, F (2, 15) = 15.32; p = 0.0003 and 0.0208 respectively). Viremia peaked
five days post-challenge in pigs 264 and 266 that survived until the end of the experiment and were
lower than those detected in the pigs that were euthanized. From six days post-challenge, a progressive
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decrease in viremia levels was observed in these two animals. Despite the absence of clinical signs and
temperatures over this period of time, low levels of infectious virus persisted in pigs 264 and 266 until
the end of the experiment (Figure 4I and Figure S4).
Figure 4. Clinical and virological parameters in experiment 1. Mean temperatures (A), clinical scores
(B) up to four days and viremia three days post-challenge (C) of groups of six pigs primed and boosted
with Antigen Pool A (blue), Antigen Pool B (red) or influenza NP (green). Temperatures (D,G,J) and
clinical scores (E,H,K) for each individual pig immunized with influenza NP (D,E), Antigen Pool A
(G,H) or Antigen Pool B (J,K) are shown. Blood was taken from animals immunized with Influenza NP
(F), Antigen Pool A (I), Antigen Pool C (L) on the indicated days and DNA was extracted in duplicate
and the viral titer determined by qPCR, with each extraction tested in duplicate. Data points are
the mean of the duplicate extractions. Errors bars on panels A, B and C indicate standard deviation
from the mean. Asterisks on panels B and C show significant differences in the indicated group of
pigs compared to the control. Temperatures and clinical scores were assessed by repeated-measures
two-way ANOVA, * p ≤ 0.05, ** p ≤ 0.01 or *** p ≤ 0.001.
3.3. Evaluation of Macroscopic Lesions and Viral Load in the Tissues in Experiment 1
During necropsies, a descriptive evaluation of lesions was carried out, but without following
any scoring system. Apart from protected pigs given Pool A (pigs 264 and 266), the rest of the pigs
immunized with Pool A (4 of 6 pigs) and Pool B (6 of 6 pigs) showed macroscopic lesions characteristic
of acute forms of ASF such as mild hydropericardium and pulmonary congestion, mild to moderate
ascites, mild to moderate hyperemic splenomegaly, lymphadenopathy with petechiae as well as
hemorrhagic lymphadenopathy that affected mainly renal and gastrohepatic lymph nodes, and renal
hemorrhages among others lesions. Significant differences were found in the viral load in some
tissues of animals immunized with the different pools of antigens and those seen in the controls
(Figure S5). The viral yield was approximately 1000-fold lower in the gastro-hepatic lymph node
of the animals given Antigen Pool A and 100-fold lower than animals given Pool B compared to
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the controls. Compared to the controls viral load was greater than 100-fold less in the retropharyngeal
lymph node of pigs immunized with either Antigen Pool A or Pool B. These differences were still
significant if the two pigs that survived (264 and 266) and were culled two weeks later than the other
animals, were omitted from the analysis.
3.4. Immune Responses after Challenge in Surviving Animals in Experiment 1
Titers of ASFV-specific antibodies measured by IFA did not increase seven days post-challenge
(66 days post-prime) in comparison to their pre-challenge levels (Figure 1A). This was also reflected
in the responses to the individual proteins that were measured by indirect ELISA, B602L, CP204L
and E183L (Figure 1C,E,F). No increase in IgG specific for B602L and CP204L after the challenge was
detected in the sera of pigs 264 and 266 (Figure S6). This suggested that challenge with virulent ASFV
did not provoke a secondary humoral immune response, although we did not test the response to all
of the proteins that comprised Antigen Pool A. There was no response to B646L prior to challenge,
however high ODs were observed in ELISAs at the end of the study to B646L and also to B602L and
CP204L. Pigs that have recovered from natural infection with ASFV typically have B646L-specific
antibodies in the circulation [45] and the absence of an increase in the response to any of the proteins
we tested 7 days post-challenge makes it possible that the antigen-specific responses detected at the end
of the experiment represent primary immune responses to the virus, rather than secondary responses
to the individual antigens. Numbers of ASFV-specific IFNγ secreting cells in the peripheral blood
increased after challenge in both animals 264 and 266 (Figure 2A, F (3, 12) = 33.23; p = 0.0061 and
p = 0.0054 respectively). However, the response to the individual antigens appeared to be dependent
on the pig with 266 showing increased responses to pools of peptides corresponding to CP204L
(Figure 2B), B646L (Figure 2H) and EP153R (Figure 2K) seven days post-challenge (day 66). Analysis
of the responses in pig 264 was limited due to the lack of viable cells pre-challenge, however, unlike
animal 266 only the responses to B602L and EP153R out of the individual antigens were higher on day
66 than they were two weeks post-boost (day 42).
3.5. Immune Responses in Experiment 2
Both Antigen Pool A and Pool B induced virus- and antigen-specific immune responses
(Figures 1–3) and both groups of animals showed reduced clinical signs and viremia or viral load in
the tissues relative to the controls (Figure 4A–C). Clearly, the most striking difference was seen in
the two animals vaccinated with Pool A (264 and 266) which recovered from a transient fever and were
then clinically normal until the end of the experiment. Pigs 264 and 266 had elevated ASFV-specific
IFNγ secreting cells in the bloodstream two weeks post-boost relative to the other animals immunized
with Antigen Pool A (Figure 2A) therefore we considered that increasing the dose of viral vectors or
reducing the number of antigens in the pool may lead to an increase in the cellular response after prime
and boost. In experiment 2, groups of six pigs were immunized with Antigen Pool A using the same
schedule as in experiment 1 except the dose of each rAd was increased three-fold to 1.5 × 1010 IU and
each MVA two and half times to 2 × 108 pfu per dose. Antigen Pool C comprised a sub-pool of Antigen
Pool A and included B646L, CP204L, E199L, F317L and MGF505-5R.
As seen in experiment 1, ASFV-specific antibodies were observed by IFA in the groups of pigs
immunized with the two antigen pools after prime and these were elevated after the boost (Figure 5A).
Titers were higher on day 59 when compared to day 28 in pigs immunized with Antigen Pool A, but not
in those immunized with Antigen Pool C (F (2.467, 24.67) = 25.13; p = 0.0239 and p = 0.1407 respectively)
suggesting that the boost had a small effect on the levels of ASFV-specific serum antibodies. There was
no difference in the titers between the two groups of pigs, nor when titers were compared to those seen
in experiment 1, suggesting the increased dose of virus vectors in the prime and boost did not affect
the levels of ASFV-specific antibodies. Antibodies specific for B602L and CP204L were detected and
the response to E183L and B646L was poor (Figure 5B–F), antibodies to F317L were also detected by
IFA, but antibodies to EP153R, E199L or MGF505-5R were not (not shown). Although there was no
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difference in the titers of ASFV-specific antibodies between experiments 1 and 2, significant differences
were seen between the response to B602L and CP204L (Figure S7) with higher ODs observed in
experiment 2.
Figure 5. Antibody responses in pigs from experiment 2 primed with rAd encoding Antigen Pool
A (blue), Antigen Pool C (red) or influenza NP. Animals were boosted with rAd/MVA 28 days after
priming and challenged with ASFV 59 days after priming. (A) The titre of anti-ASFV antibodies
in the serum of the indicated animals was determined by immunoperoxidase assay. Antibodies to
ASFV proteins B602L (B), CP204L (C,D), E183L (E) and B646L (F) were detected in 1:100 dilutions of
serum collected from the indicated animals at the indicated times post-prime by ELISA, and expressed
as the absorbency at 620 nm. Timing of boost (Bo) and challenge (Ch) are indicated on panels B to
F. Data points on panel F represent values from individual animals and are labelled as on panels
D (Antigen Pool C) and E (Antigen Pool A). Differences between antibody titres were assessed by
repeated-measures two-way ANOVA,* p ≤ 0.05.
Analysis of the cellular response showed that immunization primed ASFV-specific IFNγ-secreting
cells in both groups of pigs (Figure 6). The boost did not increase the numbers of IFNγ-secreting cells
and there were no differences between the numbers of ASFV-specific, IFNγ-secreting cells in the pigs
immunized with Antigen Pool A and those given Antigen Pool C. Comparing the responses induced
by Antigen Pool A between experiment 1 and 2 showed that increasing the dose did not increase
the number of circulating ASFV-specific, IFNγ-secreting cells. Antigen-specific cellular responses were
detected to all of the individual antigens in the pigs that were tested (Figure S8), however, the numbers
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of EP153R specific responses were very low in all of the animals except in pig 463, which also had
a poor response to B602L. There were no qualitative differences in the responses to individual antigens
between the pigs that we were able to test that had been immunized with either Antigen Pool A
or Antigen Pool C, although unfortunately there was insufficient material to test all of the animals
and perform a thorough statistical analysis. Taken together, Antigen Pool A and Antigen Pool C
delivered by rAd and boosted with a combination of rAd and MVA induced ASFV-specific cellular
immune responses that were indistinguishable from each other. Antigen-specific responses two weeks
after boost (day 42) determined in an additional two pigs from experiment 1 were used to make
a comparison of cellular responses between the two experiments (Figure S7B). No differences were
observed with the exception of MGF505-5R where the number of IFNγ secreting cells was slightly
higher in experiment 1.
Figure 6. Virus-specific IFNγ responses in animals from experiment 2 immunized with Antigen Pool A
(blue), Antigen Pool B (red) or influenza NP (green). The number of ASFV-specific IFNγ producing
PBMC were enumerated following in vitro stimulation with ASFV by ELIspot on the indicated days
post-prime. Data points indicate the number of spots per million cells induced by the whole virus after
background subtraction, error bars indicate standard deviation from the mean. Note that to aid clarity
the scale for the virus-specific responses have been set differently to those in Figure 2.
3.6. Antigen Pool A Protected 100% of Pigs from Fatal Disease
Four weeks after boost, all animals were challenged with the virulent OUR T88/1 strain of ASFV.
Three days after the challenge, pigs in all experimental groups developed pyrexia, with temperatures
in some cases above 40.5 ◦C (Figure 7D,G,J). Temperatures increased progressively, surpassing 40.5 ◦C
between four and five days post-challenge in most of the animals and reaching in many cases values
above 41 ◦C. The increase in temperature of the animals was accompanied by an increase in clinical
signs of disease ranging from non-specific (lethargic animals, reduced appetite) to more severe clinical
signs as the disease progressed (animals not eating and reluctant to get up or move, increased breathing
rate, blood in feces, vomiting). Clinical scores were higher in pigs immunized with Antigen Pool A
when compared to those in the control group four days post-challenge (p = 0.0170; F (18,135) = 10.49)
whereas clinical scores in pigs immunized with Antigen Pool C were higher than those seen in pigs in
the control group (p = 0.0376; F (18, 135) = 10.49) five days post-challenge (Figure 7B).
In experiment 1 animals immunized with either Antigen Pool A or Antigen Pool B had significantly
reduced viremia 3 days post-challenge compared to the controls (Figure 4C). This coupled with
the apparent enhanced clinical signs seen in the two vaccinated groups in experiment 2 led us to
speculate that the observed disease progression could be due to an overreaction of the immune system.
Blood samples from the animals in experiment 2 that were immunized with the two antigen pools
were tested for the presence of ASFV antigen five days post-challenge using lateral flow devices.
Only animals immunized with Antigen Pool C were positive, with pig 449 clearly positive and pigs
450, 451 and 452 weakly positive. The other two animals immunized with Antigen Pool B and all of
the animals immunized with Antigen Pool A were negative. Temperatures had risen between day 4
and day 5 in all of the animals immunized with Antigen Pool B and two of the animals immunized
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with Antigen Pool A, therefore, in order to mitigate clinical signs, a single treatment with a nonsteroidal
anti-inflammatory and antipyretic drug flunixin meglumine (Finadyne, 2 mL per 45 kg bodyweight)
was administered on day 5 post-challenge to all pigs that had been immunized with either Antigen Pool
A or C. The controls were not treated as previous experience with the OUR T88/1 strain has shown that
animals can die suddenly as early as five days post-challenge [32] and therefore any potential masking
of clinical signs that could lead to the death of an animal would have been ethically unacceptable.
The treatment did not mitigate clinical signs in pigs immunized with Antigen Pool C so these animals
were euthanized, along with the pigs in the control group, the following day (6 days post-challenge).
However, temperatures and clinical signs progressively decreased in all pigs immunized with Antigen
Pool A reaching normal values, which were maintained until the animals were euthanized twenty
days after challenge.
Figure 7. Clinical and virological parameters in experiment 2. Mean temperatures (A), clinical scores
(B) up to six days and viremia up to five days post-challenge (C) of groups of six pigs primed and
boosted with Antigen Pool A (blue), Antigen Pool C (red) or influenza NP (green). Temperatures
(D,G,J) and clinical scores (E,H,K) for each individual pig immunized with influenza NP (D,E), Antigen
Pool A (G,H) or Antigen Pool C (J,K) are shown. Blood was taken from animals immunized with
Influenza NP (F), Antigen Pool A (I), Antigen Pool C (L) on the indicated days and DNA was extracted
in duplicate and the viral titer determined by qPCR, with each extraction tested in duplicate. Data
points are the mean of the duplicate extractions. Errors bars on panels A, B and C indicate standard
deviation from the mean. Black asterisks on panels B and C show significant differences (repeated
measures two-way ANOVA) of the indicated group of pigs compared to the control, * p ≤ 0.05 or
** p ≤ 0.01. Red asterisks on panels A and B show significant differences (repeated measures two-way
ANOVA) between pigs immunized with Antigen Pools A and B six days post-infection, * p ≤ 0.05
or **** p ≤ 0.0001.
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ASFV genome was detected in all pigs after challenge (Figure 7F,I,L), viremia generally increased
as temperatures and clinical signs progressed, peaking at five or six days post-challenge. Viremia
in the group of pigs immunized with Antigen Pool A or Pool C (F (4, 30) = 2.042; p = 0.0080 and
p = 0.0330 respectively) were significantly reduced compared to the controls at five days post-challenge
(Figure 7C). From seven days post-challenge, a progressive decrease in viremia levels was observed in
the pigs immunized with Antigen Pool A. Animal 465 that maintained the highest viremia until the end
of the experiment also maintained a temperature of 40 ◦C up to 11 days post-challenge. Infectious
virus persisted in all the animals immunized with Antigen Pool A until the end of the experiment
(Figure S4B).
3.7. Evaluation of Macroscopic Lesions in Experiment 2
Macroscopic lesions were assessed during necropsies following scoring methods based on previous
standardized protocols [43]. Most of the pigs included in the control group and those vaccinated with
Antigen Pool C, euthanized at 6 days post-challenge, displayed macroscopic lesions characteristic
of acute forms of ASF such as mild to moderate hyperemic splenomegaly (12/12), hemorrhagic
lymphadenitis (11/12) that affected mainly renal (11/12) and gastrohepatic lymph nodes (5/12) or skin
erythema and cyanosis on the skin of the ears (5/12) (Figure S9). On the other hand, pigs immunized
with Antigen Pool A, which survived until the end of the experiment, only showed nonspecific mild
macroscopic changes that were not characteristic of ASF.
3.8. Antibody and Cellular Responses after Challenge in Pigs Immunised with Antigen Pool A in Experiment 2
The number of circulating ASFV-specific IFNγ-secreting cells increased between day 59
(pre-challenge) and day 66 (seven days post-challenge) in all of the pigs immunized with Antigen
Pool A except for animal 464, however, taken as a group there were no significant difference between
the two-time points (p = 0.0721, repeated measures one-way ANOVA; F (1.226, 6.13) = 10.50).
The response to each antigen varied between each pig with, for example, animal 463 showing
an increase to all of the antigens, whereas 461 only showed an increase to CP204L and B602L
(Figure S8). No increase in the response to any of the antigens was detected in cells from animals 465
and 466, despite an increase in the response to the whole virus. This may suggest that the increase in
the number of ASFV-specific IFNγ secreting cells between day 59 and 66 is, in fact, a primary response
to viral infection, rather than a secondary response to the immunization regime. In addition, there
was no significant increase in the total antibody response to B602L (Figure 5B) or CP204L (Figure 5C)
or IgG specific to the two proteins between day 59 and day 66 (Figure S6). As seen in experiment 1,
most of the surviving pigs had antibodies specific for B646L/p72 at the end of the experiment despite
having none prior to challenge (Figure 5E). Taken together there was no clear correlate of protection in
the immune responses that were tested.
3.9. Clinical Outcomes Did Not Correlate with Inferred SLA Genotypes
The lack of clear correlates of protection led us to consider the genetic background of the animals
used in the two studies. Differential protection induced by a live attenuated ASFV has been observed
between NIH cc and dd minipigs that are inbred for different swine leukocyte antigen (SLA) class I and
class II molecules [26]. In addition, the eight antigens were originally selected for their immunogenicity
in the inbred Large White Babraham line of pigs which are homozygous at the SLA locus [29,46]. Low
resolution genotyping of the twenty-four pigs immunized with Antigen Pools A, B and C identified
ten SLA class I and eleven SLA class II haplotypes (Table 3). Two SLA class I and one SLA class II
haplotypes were not resolved. SLA class I haplotype Lr-22.0 occurred in eight of the twenty-four pigs
with Lr-4.0 and Lr-24.0 found in seven and five pigs respectively. Lr-0.15b was the most common SLA
class II haplotype, being identified in eleven animals, followed by Lr-0.14 and Lr-0.19a which were
found in seven and six pigs respectively. There was no clear correlation between the observed clinical
outcomes and the SLA genotype of the respective animals. Pigs 265 and 266 that were immunized
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with Antigen Pool A in experiment 1 had similar SLA genotypes, however, 266 survived to the end of
the experiment whereas 265 was euthanized five days post-challenge. The animals immunized with
Antigen Pool A in experiment 2 that survived until the end of the experiment expressed a range of SLA
alleles. Pigs 461 and 465 were homozygous for class II haplotype Lr-0.15b and 463 was homozygous
for class I haplotype Lr-4.0. Interestingly, 461 and 465 that were immunized with Antigen Pool A and
449 that was immunized with Antigen Pool C had the same inferred SLA haplotype suggesting that
the SLA genotype did not correlate with the observed clinical outcome between the two different
pools of antigens. Pig 278 that was immunized with Antigen Pool B in experiment 1 was not protected
despite encoding the same SLA haplotype as the Babraham line (Lr-55.6). Taken together, the results
suggested that the different pools of antigens identified in an inbred pig line were immunogenic across
a range of SLA genotypes and, although the number of animals used was low, that the SLA genotype
did not correlate with clinical outcomes after the challenge.
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Table 3. SLA genotypes and haplotypes of pigs. Animals 264 through 269 from experiment 1 and 461 through 466 from experiment 2 were immunized with Antigen
Pool A, animals 276 through 281 from experiment 1 with Antigen Pool B and animals 449 through 454 from experiment 2 were immunized with Antigen Pool C. SLA
genotypes of three class I genes; SLA-1, SLA-2 and SLA-3 and three class II genes; DRB1, DQB1 and DQA were determined from each pig by PCR-SSP typing. SLA
genotypes are shown as low-resolution allele groups (e.g., SLA-1*04:XX), intermediate-resolution allele strings (e.g., DRB1*04:03–04) or specific high-resolution alleles
(e.g., DQB1*02:01), for example, pig 266 bears the SLA-1*16:03 allele and one of the SLA-1*04:XX group alleles; up to two different alleles from the SLA-3*04:XX
group; and one allele from the SLA-2*04:XX group and one from the SLA-2*06:XX. The inferred class I and class II SLA haplotype is also shown for each pig, with the
high-resolution haplotype data for the Babraham (Bab) shown for reference. Pigs that recovered after challenge are highlighted by grey shading.
Exp. Group Pig ID SLA I Allele Specificity SLA II Allele Specificity Inferred Haplotype
SLA-1 SLA-3 SLA-2 DRB1 DQB1 DQA Class I Class II Complete
Bab Reference 14:02 04:03 11:04 05:01 08:01 01:03 55/55 6/6 55.6/55.6
Pool A
264 04:XX,07:XX 04:XX 02:XX,04:XX 06:01,09:XX 07:XX,08:XX 01:XX,03:XX 4/32 12b/14 4.14/32.12b
265 04:XX,16:03 04:XX 04:XX,06:XX 02:XX,04:03-04 04:XX,07:XX 02:XX,03:XX 4/24 4/19a 4.4/24.19a
266 04:XX,16:03 04:XX 04:XX,06:XX 01:XX,04:03-04 01:XX,07:XX 01:XX,03:XX 4/24 1/19a 4.1/24.19a
267 08:XX,14:01 04:XX,06:01 06:XX,12:XX 04:XX,06:XX 02:02,07:XX 01:XX,02:XX 22/62 12a/15b 22.15b/62.12a
268 04:XX,08:XX 04:XX,06:01 04:XX,12:XX 01:XX,04:XX 01:XX,02:02 01:XX,02:XX 4/22 1/15b 4.1/22.15b
269 08:XX,09:XX,15:XX 06:01,07:XX 05:XX,12:XX 04:XX,10:XX 02:02,06:XX 01:XX,02:XX 22/28 15b/23 22.15b/28.23
Pool B
276 08:XX,16:03 04:XX,06:01 06:XX,12:XX 04:XX,04:03-04 02:02,07:XX 02:XX,03:XX 22/24 15b/19a 22.15b/24.19a
277 Blank/undetected 05:XX 06:XX 09:XX,11:XX 04:XX,08:XX 02:XX,03:XX 33/33 14/26 33.14/33.26
278 04:XX,14:02 04:XX 04:XX,11:04-05 01:XX,05:XX 01:XX,08:XX 01:XX 4/55 1/6 4.1/55.6
279 11:XX,12:XX,13:01 04:XX,05:XX 04:XX,10:XX 04:03-04,09:XX 03:02-03,08:XX 02:XX,03:XX 35/43 13/14 35.13/43.14
280 11:XX,12:XX,13:01 04:XX,05:XX 04:XX,10:XX 04:03-04,09:XX 03:02-03,08:XX 02:XX,03:XX 35/43 13/14 35.13/43.14
281 08:XX,09:XX,15:XX 06:01,07:XX 05:XX,12:XX 04:XX,10:XX 02:02,06:XX 01:XX,02:XX 22/28 15b/23 22.15b/28.23
Pool A
461 07:03,08:XX 06:01 05:XX,12:XX 04:XX 02:02 02:XX 21/22 15b/15b 21.15b/22.15b
462 07:03,11:XX 04:XX,06:01 04:XX,05:XX 04:XX,09:XX 02:02,08:XX 02:XX,03:XX 21/43 14/15b 21.15b/43.14
463 04:XX 04:XX 04:XX 02:XX,09:XX 04:XX,08:XX 02:XX,03:XX 4/4 4/14 4.4/4.14
464 Blank/undetected 05:XX,07:XX 05:XX,06:XX 10:XX,11:XX 06:XX 01:XX */33 23/26 * 23/33.26
465 07:03,08:XX 06:01 05:XX,12:XX 04:XX 02:02 02:XX 21/22 15b/15b 21.15b/22.15b
466 12:XX,13:01,16:03 04:XX,05:XX 06:XX,10:XX 04:03-04,10:XX 06:XX,07:XX 01:XX,03:XX 24/35 19a/23 24.19a/35.23
Pool C
449 07:03,08:XX 06:01 05:XX,12:XX 04:XX 02:02 02:XX 21/22 15b/15b 21.15b/22.15b
450 11:XX,14:01 04:XX 04:XX,06:XX 06:XX,09:XX 07:XX,08:XX 01:XX,03:XX 43/62 12a/14 43.14/62.12a
451 04:XX,07:03 04:XX,06:XX 04:XX,05:XX 04:XX,09:XX 02:02,08:XX 02:XX,03:XX 4/21 14/15b 4.14/21.15b
452 08:XX,11:XX 04:XX,07:XX 04:XX,05:XX 04:03-04,10:XX 06:XX,07:XX 01:XX,03:XX 7/43 19a/23 7.23/43.19a
453 08:XX,12:XX,13:01 05:XX,0601 10:XX,12:XX 04:XX,04:03-04 02:02,03:02-03 02:XX 22/35 13/15b 22.15b/35.13
454 08:XX,16:03 04:XX,07:XX 05:XX,06:XX 04:03-04,10:XX 06:XX,07:XX 01:XX,03:XX 7/24 19a/23 7.23/24.19a
* One of the class I haplotypes of pig 464 may have been generated by recombination between SLA-1 of Lr-33.0 and SLA-2/SLA-3 of Lr-7.0 or 28.0, resulting in a recombinant haplotype as
SLA-1*blank/undetected-SLA-3*07:XX–SLA-2*05:XX.
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4. Discussion
Live attenuated virus vaccines induce robust immunity against related strains of ASFV, but have
suffered from a poor safety profile in the past [47]. More recent live attenuated strains generated by
targeted gene deletion do not induce chronic forms of the disease, but a reversion to virulence is still
a concern [10]. A subunit vaccine against ASFV would avoid these potential complications, be able
to differentiate infected from vaccinated animals (DIVA), and depending on the vaccine platform is
likely to be easier to manufacture than fully replicating ASFV. Recent work to identify immunogenic
proteins encoded by ASFV has significantly increased the range of potential proteins that could be
included in a subunit vaccine. However, the absence of reliable correlates of protection or a thorough
understanding of the mechanisms of immunity force a reliance on an essentially empirical approach
to selecting protective antigens. Here, we present the results of two immunization and challenge
experiments using pools of viral vectored ASFV genes that ultimately led to 100% protection against
a fatal disease.
Twelve antigens were selected based on their ability to induce immune responses in inbred
Babraham pigs using a DNA-prime VACV-boost regime [29]. We have previously shown that
viral vectored B646L and CP204L are immunogenic in outbred pigs [21] and others have shown
rAd expressing B602L and E183L induced humoral and cellular immune responses in domestic
swine [18,19,22]. Despite observing a cellular response, we were unable to detect antibody responses to
B646L in rAd-primed, MVA-boosted pigs despite other studies demonstrating B646L-specific antibody
responses after homologous rAd prime and boost [18,19,22]. The antibody response we detected to
E183L was also poor compared to that seen by other researchers. One explanation for these discrepancies
is that we did not use adjuvant in our experiments. Another possibility is that the combination of
homologous rAd prime and boost was more effective at inducing antibody responses against B646L and
E183L than heterologous rAd prime and MVA boost used in this study. MVA-vectored EP153R induced
cellular responses in the absence of antibody response [20], but to our knowledge, the remaining
antigens have not been tested in domestic swine and we were able to detect cellular immune responses
against E199L, EP364R, F317L, I329L, MGF360-11L, MGF505-4R and MGF505-5R. We have now tested
the immunogenicity of twenty-eight different ASFV genes using viral vectors and have shown that
in the majority of cases they induce antigen-specific cellular responses in pool sizes of up to twelve
vectors [21]. Analysis of the inferred SLA haplotypes showed that results from immunogenicity studies
with inbred pig lines can be applied effectively to outbred domestic swine.
The different combinations of antigens and doses tested in these experiments all induced cellular
and humoral immune responses that were capable of recognizing the whole virus. However, no clear
correlate of protection emerged that could predict the clinical outcomes after challenge with virulent
ASFV. The two animals that were protected against fatal disease in experiment 1 had the highest number
of circulating ASFV-specific, IFNγ-secreting memory cells, however, pigs in experiment 2 immunized
with Antigen Pool A that were protected had similar numbers of ASFV-specific, IFNγ-secreting
memory cells to those that were not protected in experiment 1. In addition, animals immunized
with Antigen Pool C in experiment 2 had similar levels of ASFV-specific, IFNγ-secreting cells and
these were not protected either. The limited protection that we observed with other pools of viral
vectored antigens [21] were only observed in animals with significant numbers of PBMC that secreted
IFNγ after in vitro stimulation with the whole virus. Therefore, it is tempting to speculate that
priming of ASFV-specific, IFNγ-secreting cells is necessary, but not sufficient to mediate protective
immunity. Further experiments to phenotype the cells that secrete IFNγ, to determine if they also
secrete interleukin-2 and tumour necrosis factor-α simultaneously after activation, and to determine if
they exhibit ASFV- or antigen-specific cytotoxicity, may refine our understanding of the importance of
the cellular response in protecting animals against severe disease.
We were unable to correlate ASFV-specific or antigen-specific antibody responses in individual
pigs to protection, although we did not examine the antibody responses to all of the antigens in
detail and did not determine end-point titers for the antigens in the different pools. We were also
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unable to show any effect of serum from any of the animals in these experiments on the ability of
OUR T88/1 to infect macrophages (not shown) [48]. However, it is important to note that we have
no positive control for these neutralization experiments and therefore it is possible that neutralizing
or infection-enhancing antibodies were induced in these animals and could have played a role in
the observed clinical outcomes. Conformational neutralizing antibodies against B646L have been
described [49] and generating such an immune response will likely require the formation of the trimers
in which the protein is found in assembled virions [50–52]. Formation of B646L trimers is dependent
on co-expression of B602L [53,54], however, ASFV neutralizing antibodies targeting E183L and CP204L
can be induced in pigs by recombinant protein alone [13]. Further experiments should also test for
antibody-dependent cellular cytotoxicity as this functionality has been observed in animals that have
naturally recovered from ASF [55]. The observation that the group of pigs immunized with Antigen
Pool A in experiment 2 had a more robust anti-CP204L and -B602L antibody response when compared
to experiment 1 suggests further studies on the importance of the antibody response are warranted.
Differences in the number of protected animals immunized with Antigen Pool A between
experiments 1 and 2 could have either been due to the increased dose of vectors used, the treatment
with flunixin meglumine five days post-challenge in experiment 2, or the genetic background of
the animals themselves. No evidence in support of the latter point was found after SLA haplotyping,
but many other factors play a role in the response to immunization and challenge. The temperatures of
pigs 463, 464 and 465 in Antigen Pool A had already begun to decrease from their maximum before
treatment with flunixin meglumine, pig 462 maintained a temperature of 40.4 ◦C before and after
the treatment and the temperature in pig 465 increased after intervention with flunixin meglumine.
Pigs 461 and 466 had high temperatures and had shown disinterest in food the day before treatment and
both showed improvement afterwards. Therefore, it is possible that the flunixin meglumine may have
contributed to these animals not reaching their humane end-point six days post- challenge. However,
treatment with flunixin meglumine did not prevent temperatures increasing in the animals immunized
with Antigen Pool B and all animals in this group that refused food prior to treatment refused the day
after. This is consistent with data from others that show continual treatment with flunixin meglumine
does not alleviate clinical signs induced by virulent ASFV [56]. Therefore, treatment of the animals
immunized with Antigen Pool A in experiment 2 may have prevented some of the pigs reaching
their humane endpoint six days post-challenge, however, it is unlikely to have influenced their ultimate
survival. One potential difference was that some antigen-specific antibody responses were higher in
experiment 2 than in experiment 1 suggesting the increased dose of the vector may have improved
individual responses without leading to an increase in the titer of ASFV-specific antibodies. More
detailed analysis of the responses to the other proteins in Antigen Pool A, in conjunction with improved
tools to study the function of antibodies to the whole virus will help us to determine if the enhanced
responses observed to a couple of antigens are representative of a wider importance of the antibody
response in protection.
One of the key questions is which of B602L, B646L, CP204L, E183L, E199L, EP153R, F317L and
MGF505-5R in Antigen Pool A are required for protection and as B602L, E183L and EP153R were
absent from Antigen Pool C it is likely that one or more of these play an important role. B602L and
EP153R were present in Antigen Pool B and this did not confer any protection from severe disease,
although viremia was slightly reduced compared to the control group in this experiment. However,
it is possible that some of the other antigens in Pool B may have interfered with any protective immune
responses induced by expression of B602L and EP153R, as we and others have seen vaccine-induced
disease enhancement with viral vectors [21,22]. In other studies, E183L was part of the fusion protein
used in DNA vaccination studies that induced partial protection [15] and was included in a pool of
rAd-vectored ASFV genes along with B646L and CP204L that may protect pigs [22]. Therefore, it is
possible that E183L may be an important protective antigen that was absent from Antigen Pool C. B646L
and CP204L were included with another ten antigens in a previous viral vectored vaccine study, but
did not protect animals from reaching the humane endpoints of the study [21]. F317L and MGF505-5R
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were present in all three pools of antigens tested in this study which may argue for a less important
role in protection. It is likely that antigens within Antigen Pool C in combination with one or more of
B602L and E183L, EP153R mediate the protective immune response observed in these experiments.
All of the surviving animals showed clinical signs after challenge and all of them were viremic at
the end of study, future experiments should determine whether pigs are able to clear the infection and
also if these vaccinated animals shed infectious virus that could be transmitted to naïve animals. It is
likely that additional antigens will need to be identified to provide an immune response capable of
further suppressing viral replication.
Genotype I viruses have proved useful model systems to study the protective immune response
to ASFV [2,28,57] and the genes we have used in our studies are derived from the genotype I isolates
OUR T88/3 and Benin 1997/1. Outbreaks of ASF in Eurasia since 2007 have been caused by a genotype
II virus, and cross-protection between ASFV isolates is difficult to predict [27,28,32]. With the exception
of B602L and EP153R, the identity between the Georgia 2007/1 protein sequences and those used in this
study are greater than 90% and the low virulent NH/P68 genotype I isolate can protect against challenge
with virulent genotype II virus [58,59] suggesting genotype I antigens may protect against genotype II
challenge, although there may be differences in critical T-cell or antibody epitopes. Genotype I viruses
continue to cause outbreaks across western sub-Saharan Africa [60–64] and an effective vaccine would
provide an additional control measure in this region that could aid commercial and subsistence farmers
from the devastation caused by ASF [62,64]. In order to realize such a vaccine, future work will need
to concentrate on refining the specific antigens within the 8 identified that are required for protection
against fatal disease, defining correlates of protection, determining the requirement for a boost, as well
as identifying other antigens to improve the efficacy of the immunization regime.
5. Conclusions
Viral vectors represent an attractive vaccine platform due to their ability to induce robust antigen
specific humoral and cellular immune responses as well as their excellent safety record. Adenovirus,
alphavirus and vaccinia virus vectors have all been shown to induce effective ASFV-antigen specific
responses [18–23,65]. However, despite the promising immunogenicity data these vaccination regimes
have shown limited protection after challenge with virulent ASFV and in some cases resulted in
enhanced disease. We have identified eight ASFV genes that when delivered to pigs using an adenovirus
prime and modified vaccinia Ankara boost can protect pigs against a fatal disease caused by a genotype
I ASFV strain. This data may provide the basis for development of an effective subunit vaccine against
African swine fever.
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